EUCTR2012-005586-13-ES进行中（未招募）1 期
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) - COPD
AB SCIENCE0 个研究点目标入组 30 人开始时间: 2013年6月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient with history of chronic obstructive pulmonary disease for at least 12 months prior to screening visit (ATS/ERS 2005) and chronic productive cough for 3 months in each of the 2 years prior to screening visit (if other causes of productive cough have been excluded), and present during the 4 weeks preceding screening.
- •2.Patient with at least one exacerbation during the preceding year.
- •3.Patient with FEV1/FVC ratio (post-bronchodilator) ? 70%.
- •4.Patient with FEV1 (post-bronchodilator) between ? 30 % and ? 50 % of predicted value
- •5.Patient pre-treated with adequate and stable symptomatic treatment for at least 3 months prior to screening visit.
- •6.Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years
- •7.Patient with normal organ function defined as:
- •?absolute neutrophils count (ANC) ? 2.0 x 109/L,
- •?haemoglobin ? 10 g/dL
- •?platelets (PTL) ? 100 x 109/L
- •?AST/ALT ? 3x ULN
- •?bilirubin ? 1.5x ULN
- •?creatinin clearance ? 60 mL/min
- •?albumin > 1 x LLN
- •?Proteinuria < 30 mg/dL (1+) on the dipstick. If proteinuria is ? 1+ on the dipstick, 24 hours proteinuria must be < 1.5g/24 hours.
- •8.Male or female patient, aged 40 to 75 years inclusive, weight > 50 kg and BMI between 18 and 35 kg/m²
- •9.Man and woman of child bearing potential, must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.
- •10.Female patient of childbearing potential must have a negative pregnancy test at screening and baseline
- •11.Patient able and willing to comply with study procedures as per protocol.
- •12.Patient able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first 2 months.
- •13.Patient able to understand, sign, and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Pregnant, or nursing female patient
- •2.Patient experiencing COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to the screening visit.
- •3.Patient with lower respiratory tract infection not resolved 4 weeks prior to the screening visit.
- •4.Patient with asthma and/or other relevant lung disease (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], and active tuberculosis).
- •5.Patient currently participating in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the screening visit.
- •6.Patients with known alpha-1-antitrypsin deficiency.
- •7.Patient with clinically significant cardiopulmonary abnormalities (diagnosed clinically or by X-ray / CT-scan / ECG) that are not related to COPD and that require further evaluation.
- •8.Patient who had major surgery within 2 weeks prior to screening visit
- •9.Patient presenting with cardiac disorders defined by at least one of the following conditions:
- •?Patient with recent cardiac history (within 6 months) of:
- •-Acute coronary syndrome
- •-Acute heart failure (class III or IV of the NYHA classification)
- •-Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- •?Patient with cardiac failure class III or IV of the NYHA classification
- •?Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- •?Syncope without known aetiology within 3 months
- •?Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •10.Patient with:
- •?Life expectancy < 6 months
- •?< 5 years free of malignancy, except treated basal cell skin cancer or cervical carcinoma in situ
- •?Any severe and/or uncontrolled medical condition
- •?Patient with an active infection (Human immunodeficiency virus infection and/or hepatitis B or C infection, tuberculosis...)
- •11.Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •12.Treatment with any investigational agent within 4 weeks prior baseline
研究者
相似试验
进行中（未招募）
不适用
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2010-021495-29-FRAB Science
进行中（未招募）
不适用
A study of a new iron medication for people with Crohn's Disease that is in remission and anaemia (low number of healthy red blood cells), who cannot use other oral iron medications either because they do not work, or because they cause side effects. (AEGIS 2)Iron deficiency anaemia in quiescent Crohn's DiseaseMedDRA version: 14.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-023589-39-ATIron Therapeutics (Switzerland) AG60
进行中（未招募）
1 期
Evaluation of masitinib in acute ischemic strokepatients suffering from Acute Ischemic StrokeMedDRA version: 18.1Level: LLTClassification code 10023027Term: Ischaemic stroke NOSSystem Organ Class: 100000004852EUCTR2010-020603-79-SKAB Science48
进行中（未招募）
不适用
Clinical study for the assessment of the efficacy and the safety of masitinib versus placebo in the treatment of patients with severe COPD with elevated eosinophils level.EUCTR2012-005586-13-GRAB Science45
进行中（未招募）
不适用
A study of a new iron medication for people with Crohn's Disease that is in remission and anaemia (low number of healthy red blood cells), who cannot use other oral iron medications either because they do not work, or because they cause side effects. (AEGIS 2)Iron deficiency anaemia in quiescent Crohn's DiseaseMedDRA version: 14.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-023589-39-HUIron Therapeutics (Switzerland) AG60